Sirtuins and the Metabolic Hurdles in Cancer  by German, Natalie J. & Haigis, Marcia C.
Current Biology
ReviewSirtuins and the Metabolic Hurdles in CancerNatalie J. German and Marcia C. Haigis
Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
*Correspondence: njgerman@fas.harvard.edu (N.J.G.), marcia_haigis@hms.harvard.edu (M.C.H.)
http://dx.doi.org/10.1016/j.cub.2015.05.012
The nutrient demands of cancer cannot be met by normal cell metabolism. Cancer cells undergo dramatic
alteration of metabolic pathways in a process called reprogramming, characterized by increased nutrient up-
take and re-purposing of these fuels for biosynthetic, bioenergetic or signaling pathways. Partitioning carbon
sources toward growth and away from ATP production necessitates other means of generating energy for
biosynthetic reactions. Additionally, cancer cell adaptations frequently lead to increased production of reac-
tive oxygen species and lactic acid, which can be beneficial to cancer growth but also are potentially toxic
andmust be appropriately cleared. Sirtuins are a family of deacylases and ADP-ribosyltransferaseswith clear
links to regulation of cancer metabolism. Through their unique ability to integrate cellular stress and nutrient
status with coordination of metabolic outputs, sirtuins are well poised to play pivotal roles in tumor progres-
sion and survival. Here, we review themulti-faceted duties of sirtuins in tackling themetabolic hurdles in can-
cer. We focus on both beneficial and adverse effects of sirtuins in the regulation of energetic, biosynthetic
and toxicity barriers faced by cancer cells.Introduction
It is more relevant than ever to understand how metabolism
influences tumor growth. Bioenergetic and biosynthetic depen-
dencies of cancer cells are increasingly being realized as prom-
ising candidates for therapeutic interventions in cancer [1–3].
A vast number of studies validate the notion that metabolic
dysfunction is not just a consequenceof cancer growth but rather
adriving factor in tumor progression [4,5]. Indeed, alterednutrient
utilization enables tumor cells to fuel anumber of processes, such
as amassing a pool of biosynthetic precursors, constructing
signaling molecules, generating molecules for post-translational
or epigenetic modifications, and maintaining pH and redox
homeostasis [6,7]. Furthermore, metabolic dysfunction has posi-
tioned itself at the forefront of cancer research with the recogni-
tion of the undeniable connectionbetween increasedcancer inci-
dence and the background of obesity and metabolic disease,
pathologies that have reached epidemic proportions in the
UnitedStates andmuchof theworld [8–11]. It is critical to fully un-
derstand how tumor cells alter fuel usage and to identify path-
ways that might promote or oppose this metabolic dysfunction.
Sirtuins are a highly conserved family of regulatory enzymes
that are well poised to play pivotal roles in tumor metabolism.
The seven mammalian sirtuins (SIRT1–SIRT7) have the unique
ability to integrate the cellular stress response with the coordina-
tion of metabolic fitness and homeostasis [12,13]. The role of
sirtuins as post-translational modifying enzymes may have orig-
inated to allow survival under stress and low nutrient conditions,
and many of these functions have now been linked to growth
regulation in the harsh conditions experienced by cancer cells
[14–16]. In recent years, a number of studies have shown that sir-
tuins not only coordinate cancer cell growth and survival, but
also regulate the nutrient state of a tumor [17,18]. There is
growing interest in pinpointing metabolic regulatory nodes that
can be targeted in cancer treatment and determining whether
sirtuins specifically may be promising biomarkers or therapeutic
targets in cancer.Current Biology 25, R569Here, we review the roles of sirtuins in themetabolic hurdles of
cancer. We will first overview sirtuin enzymatic activity and links
to cancer incidence and severity. Then we will discuss sirtuin-
mediated control of metabolic pathways with a focus on glucose
metabolism, refilling of the tricarboxylic acid (TCA) cycle and
in defense against reactive oxygen species (ROS) in cancer.
Sirtuins coordinate many other processes linked to cancer,
including DNA repair, metastasis, apoptosis and translation: for
reviews more comprehensively assessing those roles, we refer
the reader to other sources (such as [13,14,19]).
Connections between Sirtuin Activity and the Metabolic
State
Sirtuin Enzymatic Activity
SIRT1–SIRT7 are a family of deacylases and ADP-ribosyltrans-
ferases that share a conserved catalytic core domain but vary
in subcellular localization and preferred substrates [20]. The dif-
ferences between sirtuins lead to variations in the ultimate meta-
bolic effect that is coordinated by each sirtuin [15]. SIRT1, SIRT6
and SIRT7 are primarily nuclear and regulate transcription fac-
tors and histone modifications to coordinate gene expression
programs that can direct the cellular metabolic state [21]. Cyto-
solic functions of SIRT1 have also been identified. SIRT2 is
largely cytosolic and coordinates microtubule dynamics as well
as the activity of transcription factors residing outside the nu-
cleus [22,23]. Localization of SIRT3, SIRT4 and SIRT5 in the
mitochondrial matrix enables these sirtuins to directly alter the
activity of many metabolic enzymes [24].
Sirtuins catalyze nicotinamide adenine dinucleotide (NAD+)-
dependent deacylation or ADP-ribosylation reactions with vary-
ing degrees of substrate versatility [20]. Although originally
referred to as deacetylases, sirtuins are now classified more
broadly as deacylases. This term accounts for the ability of
certain sirtuins to remove not only acetyl groups from lysine
residues, but also other acyl modifications, including propionyl,
butyryl, malonyl, succinyl and the lengthy fatty-acid-derived–R583, June 29, 2015 ª2015 Elsevier Ltd All rights reserved R569
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Figure 1. Sirtuin-catalyzed reactions.
(A) During deacylation reactions, sirtuins direct NAD+ to nucleophilically attack the acylated lysine residue, leading to removal of the acyl modification. NAD+ is
cleaved in the process, forming nicotinamide and 2’-O-acyl ADP-ribose. Sirtuins can potentially remove diverse acyl modifications (inset) from lysine residues. (B)
During ADP-ribosylation reactions, sirtuins use NAD+ to nucleophilically attack an arginine (shown) or cysteine residue. NAD+ is cleaved, resulting in release of
nicotinamide and transfer of the ADP-ribose portion of NAD+ to the substrate residue.
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Reviewmyristoyl and palmitoyl groups [25]. SIRT5, for example, is a
strong desuccinylase, and SIRT4 was recently reported to func-
tion as a lipoamidase by removing lipoyl or biotinyl modifications
from lysine residues [26]. Through these processes, sirtuins have
been shown to alter substrate activity, localization, stability and
protein–protein interactions [14].
Regardless of which type of substrate moiety is modified by
sirtuins, a similar NAD+-dependent reaction mechanism pro-
ceeds. During sirtuin-catalyzed deacylation (Figure 1A), NAD+
nucleophilically attacks an acyl group of a substrate lysine. The
resulting intermediate is cleaved to form 2’-O-acyl-ADP ribose
(OAADPR) and nicotinamide, and the acyl group is removed
from the lysine residue in the process. In sirtuin-catalyzed
ADP-ribosylation (Figure 1B), NAD+ similarly attacks a substrate
residue, typically an arginine residue [27], although cysteine res-
idues are also candidate sites [28–30]. The ADP-ribose portion of
NAD+ is transferred to the substrate residue, yielding nicotin-
amide as a side product [31,32].
The metabolic by-products of sirtuin activity have potential to
accumulate and influence cellular biology. At high concentra-
tions, nicotinamide inhibits sirtuin function [33]. Work by Grubi-
sha et al. [34] showed that pools of OAADPR generated by
certain sirtuins bind and inhibit the non-selective cation channel
TRPM2. This channel is normally activated by oxidative or nitra-
tive stress as well as by the drug puromycin, which directly tar-
gets TRPM2 [34,35]. Activation of this channel leads to an influx
of Na2+ andCa2+ into the cytosol to induce cell death. Decreased
expression of SIRT2 and SIRT3 dampened TRPM2-mediatedR570 Current Biology 25, R569–R583, June 29, 2015 ª2015 Elseviercell death in response to puromycin. Of note, quantitative studies
of OAADPR have been impeded by the rapid hydrolytic degrada-
tion of this molecule to ADP-ribose in cells [36]. The role of sir-
tuin-derived metabolites is a promising and little studied area
of sirtuin biology.
Sirtuins and NAD+ Sensitivity
Sirtuins are unique sensors of the metabolic state because their
NAD+-dependent enzymatic activity intrinsically couples their
function to the metabolic status of the cell or organism [37–41].
According to the metabolic state of the cell, the ratio of NAD tog-
gles between varying amounts of NAD+ and NADH [42]: NADH is
a high-energy, reduced form of NAD that can donate electrons to
the electron transport chain, and NAD+ is the lower energy,
oxidized counterpart required to fuel glycolysis. When the cell
uses oxidative metabolism, NADH generated by the TCA cycle
and glycolysis donates electrons to complex I of the electron
transport chain (ETC). This contributes to a proton gradient
that will ultimately produce ATP. Upon electron transfer, NADH
is oxidized back to NAD+. In highly glycolytic cells with low
ETC function, NAD+ is alternatively regenerated from NADH via
lactate dehydrogenase (LDH) activity in order to sustain glycol-
ysis. NAD+ can also be synthesized de novo from tryptophan
and vitamin B3 derivatives, or via salvage pathways using nico-
tinamide or nicotinamide riboside. Thus, the NAD+:NADH ratio is
affected by the cellular metabolic state, and changes in this ratio
have potential to impact sirtuin enzymatic activity.
Several studies have linked sirtuin activity with the organismal
metabolic status and cellular NAD ratio. In many tissues, theLtd All rights reserved
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ReviewNAD+:NADH ratio is low during nutrient excess and high during
nutrient deprivation [43,44]. For example, in skeletal muscle
and white adipose, the NAD+:NADH ratio is elevated during cal-
orie restriction [45]. Due to their dependency on NAD, it is not
surprising that certain sirtuins are reported to have increased ac-
tivity in response to high NAD+ levels [46]. For example, SIRT1 in
skeletal muscle and brain is activated by exercise, fasting and
calorie restriction [47–49]. In contrast, low NAD+ levels are
observed with obesity as well as old age, two factors that confer
increased risk for many cancers and are also linked to decreased
sirtuin activity [50,51]. Along these lines, growing evidence sug-
gests that loss of sirtuin function plays a role in obesity- and age-
associated cancers [8,52].
It is proposed that there are tissue-type and cellular-compart-
mentalization variations in NAD+ and NADH levels that may lead
to distinct alterations of sirtuin activity in different contexts [42].
NAD+ is generated by biosynthetic reactions in themitochondria,
nucleus and cytosol [53]. Generally NAD+ is most abundant in
mitochondria, particularly in highly metabolically active tissues,
such as cardiac myocytes, although the distribution varies
across cell types [54]. Nuclear NAD+ can be depleted upon
DNA damage when this molecule is used as a substrate for the
poly(ADP-ribose) polymerase (PARP) family of enzymes to acti-
vate DNA repair pathways [55]. Inhibiting PARPs elevates
NAD+ levels, presumably in the nucleus, and accordingly was
shown to boost activity of nuclear SIRT1 and not mitochondrial
SIRT3 [56]. Upon PARP activation, the mitochondrial perme-
ability transition pore opens to allow flow of NAD+ from mito-
chondria to the cytosol and nucleus in order to allow further
PARP function. Work by Yang et al. [38] suggests that upregula-
tion of NAD+ biosynthesis enables mitochondrial NAD+ to be
maintained at physiological levels even though cytosolic and
nuclear NAD+ pools are depleted upon genotoxic stress. Promo-
tion of NAD+ biosynthesis in the mitochondria was further indi-
cated to be dependent on SIRT3 and SIRT4 [38]. It will be useful
for future studies to validate these NAD+ measurements in live
cells in order to avoid the reliance on subcellular fractionation.
Other Regulation of Sirtuins
It is important to point out that sirtuin activity is not solely depen-
dent on NAD+ levels. Transcriptional, post-translational and
allosteric regulation are all important physiological modulators
of sirtuin activity [57]. A major negative regulator of SIRT1 with
relevance in cancer is deleted in breast cancer-1 (DBC1), a
nuclear protein that functions as a tumor suppressor and is ho-
mozygously deleted in some breast cancers [58]. DBC1 inhibits
SIRT1 by directly binding to its catalytic domain [58,59]. This
repressive interaction is induced upon DNA damage down-
stream of ATM, a key mediator of the DNA damage response
that acts as a kinase targeting multiple proteins including
DBC1 [60,61]. Phosphorylation of DBC1 creates an additional
SIRT1-binding site. Strong repression of SIRT1 in this manner
stimulates apoptosis, a proper cellular response to excessive
genotoxic damage in many contexts. An AMP-activated protein
kinase (AMPK)-dependent pathway disrupts the DBC1–SIRT1
interaction via phosphorylation of SIRT1 [62,63]. AMPK is a
cellular sensor of a low-energy state that acts as a bioenergetic
rheostat by phosphorylating many metabolic proteins to restore
energetic homeostasis [47]. Indeed, AMPK has been linked to
activation of SIRT1 under low-energy conditions in multipleCurrent Biology 25, R569studies and via multiple proposed mechanisms [47,64]. SIRT1
activity is also dramatically enhanced upon phosphorylation by
additional kinases in response to adrenergic signaling and
stresses such as DNA damage, microtubule disruption and
heat or cold shock [65,66]. Phosphorylation at one particular
site, Thr522, boosts SIRT1 activity by promoting its monomeric
state rather than its oligomeric, aggregation-prone state [67].
In the case of SIRT4, activity likely does not parallel the cellular
NAD+ level. SIRT4 plays a key role in inhibiting fat catabolism
when mice are well fed, despite the low levels of NAD+ expected
under this condition [68]. SIRT4 mRNA and protein are more
abundant in mouse tissues under fed versus fasted conditions
[69,70]. SIRT4 mRNA is also highly induced by DNA damage
and inhibition of mammalian target of rapamycin (mTOR), dis-
cussed further below [71,72]. SIRT6 activity in vitro is induced
by fatty acids [25]. It will be important for future studies to reveal
further molecular mechanisms bywhich sirtuin levels and activity
are regulated, whether it is via post-translational modification,
transcriptional control, or even mRNA stability.
Connections between Sirtuins and Cancer
The associations between cancer metabolism and sirtuins often
fall into one of two themes. First, loss of sirtuin activity may result
in increased susceptibility to cancer onset. Second, and some-
what paradoxically, an already established tumor that expresses
high levels of some sirtuins may possess survival advantages,
including resistance to chemotherapeutics.
On the one hand, loss of sirtuin activity has been shown to
contribute to cancer onset in numerous studies. The link be-
tween sirtuin loss and tumor emergence is evidenced by several
models where SIRT1, SIRT2, SIRT3, SIRT4, or SIRT6 knockout
mice are more prone to cancer incidence [13,19]. Overexpres-
sion of SIRT1 in the gut epitheliumwas found to suppress tumor-
igenesis in a mouse model of colon cancer [73], although other
groups have drawn the opposite conclusion [74,75]. Further
studies are needed to clarify this discrepancy. In humans,
SIRT3 protein and mRNA levels are strongly decreased in breast
and ovarian cancer [76]. SIRT4 expression is decreased in lung,
breast, bladder and gastric cancer and specific leukemia sub-
types [71,72]. SIRT6 levels are reduced in colon carcinoma and
pancreatic cancer [77]. The metabolic state maintained by sir-
tuins can be particularly incompatible with the onset of cancer,
as discussed further below.
On the other hand, however, in certain established tumors it is
possible that sirtuins have pro-tumorigenic roles by promoting
survival under the stress conditions that dominate the cancer
cell state. For example, high SIRT1 expression is observed in
drug-resistant cancers [78]. In numerous studies, SIRT1 levels
are elevated in human cancer relative to normal tissue. In fact,
maintaining SIRT1 expression appears so vital for cancer cells
that there are no reported deletions of SIRT1 in cancer and
only extremely rare instances of SIRT1mutation [13]. Thus, while
SIRT1 may counter the onset of cancer, an established tumor
can greatly benefit from ramping up SIRT1 expression to induce
pro-survival pathways [79]. Expression of another nuclear sirtuin,
SIRT7, promotes survival of cancer cells and maintenance of
a transformed state [80]. In breast, thyroid and liver cancer,
SIRT7 is upregulated [13]. The mitochondrial sirtuin SIRT3 pro-
motes oral squamous cell carcinoma by preventing apoptosis–R583, June 29, 2015 ª2015 Elsevier Ltd All rights reserved R571
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Reviewof cancer cells [81]. This report is in line with a human genetics
study showing that an extra germline copy of SIRT3 limits
apoptosis in glioma cells and predisposes patients to brain
tumors [82]. Thus, while sirtuins in many cases can suppress
cancer formation, sirtuins can also enhance the growth of
some tumors, depending on the cancer type, stage and accom-
panying mutations. A more comprehensive understanding of
sirtuin functions and relevant targets in cancer may shed light
on the pro- or anti-tumorigenic roles of sirtuins in particular tumor
types.
Altered Glucose Metabolism in Cancer and Regulation
by Sirtuins
In many cancers, metabolic reprogramming is characterized
by increased glucose uptake [83]. Glucose is predominantly
used for biosynthetic purposes; intermediates of glycolysis are
directed toward pathways that build macromolecules, including
nucleotides, lipids and proteins. In addition to biosynthesis,
glucose contributes to ATP production, generation of signaling
molecules and antioxidants, and production of lactate, which
can acidify the tumor microenvironment to promote migration,
genetic instability and cancer cell stemness [84–87]. Upregula-
tion of glycolysis and lactic acid production even under normoxia
when mitochondria are functional is termed the ‘Warburg effect’.
Elevated glycolysis can additionally fuel ATP production, even
under hypoxic conditions in cancer cells. Rapidly growing or
metastatic tumors often have low oxygen due to inadequate
blood supply. In the absence of sufficient oxygen, mitochondrial
ATP production is limited [88]. To circumvent an energetic
deficit, glycolysis can be upregulated to generate ATP via sub-
strate-level phosphorylation. The amount of ATP produced by
glycolysis is only a fraction of that generated by the electron
transport chain; however, greatly induced glycolysis could sup-
port bioenergetic homeostasis when oxygen is limiting [89].
HIF, PHDs and Metabolic Stress Sensing
One mechanism by which sirtuins have been shown to control
glycolysis is via regulation of the hypoxia-inducible factor (HIF)
signaling pathway. HIF is a master transcriptional activator of
glycolysis with strong links to cancer and functions as an a/b het-
erodimer [90]. Of the three HIFa isoforms, HIF1a and 2a are the
most well-studied [91]. Increased levels of HIF1a and HIF2a are
observed in many cancers and correlate with worse prognosis
[92]. While HIF1a and HIF2a have overlapping target genes, a
number of genes are exclusively modulated by just one HIF iso-
form. In healthy cells, HIF is activated under hypoxia to promote
glycolytic metabolism along with other pathways that mediate
cell survival under low oxygen. However, under some conditions
of cellular oxidative stress and in many cancers, aberrantly acti-
vated HIF facilitates metabolic reprogramming and upregulation
of glycolysis even when oxygen levels are sufficient [93]. Physi-
ologically under normoxia, HIF transcriptional activity is limited
to a low, basal level. Cytosolic HIFa is hydroxylated by oxy-
gen-dependent prolyl hydroxylase domain (PHD) enzymes and
subsequently ubiquitinated by the von Hippel-Lindau (VHL) E3
ubiqutin ligase, targeting HIFa for degradation [94].
Under hypoxia, PHD activity is inhibited by low oxygen avail-
ability and HIFa is stabilized. HIFa translocates to the nucleus
and forms a heterodimer with HIFb (also called aryl hydrocarbon
nuclear receptor, ARNT) resulting in a functional transcriptionR572 Current Biology 25, R569–R583, June 29, 2015 ª2015 Elsevierfactor in complex with the coactivator p300/CBP [95]. This com-
plex binds hypoxia-responsive elements in promoters of target
genes to activate a transcriptional program that boosts angio-
genesis, erythropoiesis and glycolytic metabolism [96].
Much like sirtuins, PHDs are perfectly poised to elicit meta-
bolic alterations in response to changing nutrient availability or
stress. PHDs are a family of a-ketoglutarate-dependent dioxyge-
nases that hydroxylate proline residues of target proteins [97,98].
There are three main mammalian PHDs (also called egg laying
defective nine, or Egln, proteins in reference to their originally
described function in egg laying in Caenorhabditis elegans)
[99]. A little-studied fourth PHD family member is located in the
endoplasmic reticulum [100]. During catalysis, PHDs transfer
one atom of molecular oxygen to a proline residue of a substrate
protein, resulting in prolyl-hydroxylation. The other oxygen atom
is transferred to a-ketoglutarate which is subsequently decar-
boxylated to form carbon dioxide and succinate [97]. PHD cata-
lytic activity is sensitive to several key molecules that can be
viewed as indicators of the cellular metabolic state: oxygen,
ROS and specific TCA cycle intermediates [91]. In response to
changing levels of these inputs, PHDs have been shown to insti-
gate HIF-driven metabolic changes that restore homeostasis
and redox balance.
Because the PHD catalytic mechanism requires molecular
oxygen, a drop in intracellular oxygen levels can decrease PHD
activity and consequently stabilize HIF [88]. Two PHD family
members, PHD1 and PHD2, are quite sensitive to subtle
changes in cellular oxygen levels due to their weak affinity for
oxygen, with the Km for oxygen being only slightly higher than
the normal oxygen concentration in the cell. This suggests
PHD1 and PHD2 normally operate at sub-optimal conditions
and any drop in oxygen can potentially make PHDs much less
active [96]. Oxygen sensing by PHD1 and PHD2 situates these
enzymes as integral components in the HIF-driven transcrip-
tional response to low intracellular oxygen. PHD activity is
frequently repressed in tumors that have become hypoxic due
to excessive oxygen consumption or insufficient blood supply
[101].
The use of a-ketoglutarate as a co-substrate makes PHDs
sensitive to TCA cycle imbalances that are observed in some
cancers. Thus, PHD activity and HIF stability can be regulated
even under normoxic conditions. At high concentrations, succi-
nate and fumarate competitively inhibit the PHD-binding site that
is normally occupied by the structurally similar molecule a-keto-
glutarate [102,103]. In some tumors, deficiencies in the TCA
cycle enzymes succinate dehydrogenase and fumarate hydra-
tase lead to a build-up of succinate and fumarate, respectively
[104]. The overabundance of these metabolites inhibits PHD
function and is linked to HIF-driven metabolic reprogramming
in cancer.
PHD enzymatic activity is intrinsically sensitive to redox status
due to the requirement for reduced iron in the catalytic site. The
PHD catalytic domain contains a conserved triad of two histi-
dines and one aspartate that coordinate iron [105]. To enable
oxygen binding at this catalytic site, iron must be maintained
in the reduced (Fe2+) state, a function achieved, in part, by
the cellular antioxidants ascorbate (vitamin C) or glutathione
[106,107]. Under conditions of high intracellular ROS, these anti-
oxidant molecules may be depleted leading to oxidation of theLtd All rights reserved
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Figure 2. Sirtuin-mediated repression of the basal HIF response and glycolytic metabolism during normoxia.
(A) Sirtuins obstruct HIF-mediated reprogramming of cell metabolism under normoxia. HIF activity is restricted under normoxia due to proteasomal degradation
of HIF1a, which is triggered by PHD family members and the p-VHL ubiquitin ligase. Degradation prevents movement of HIF1a to the nucleus. In mitochondria,
SIRT3 limits ROS levels, thus helping maintain PHD function so that HIF1a can be degraded. In the cytosol, SIRT2 represses basal HIF1a by direct deacetylation.
Any HIF1amolecules that do enter the nucleus are deacetylated and repressed by SIRT1. SIRT6 also inhibits HIF1a in the nucleus via direct binding to HIF1a at
hypoxia-responsive elements (HRE) on gene promoters, preventing formation of a functional transcription factor complex. SIRT6 further represses HIF1-
regulated genes by deacetylating histone H3K9 at glycolytic gene promoters. (B) Loss of sirtuin activity, for example during the transition to cancer or in genetic
mouse knockout models, leads to activation of HIF1-mediated glycolytic metabolism even under normoxia. In the absence of SIRT3, ROS levels increase and
inhibit PHD-catalyzed hydroxylation of HIF1a. Also, in the absence of specific sirtuins, HIF1a is hyperacetylated andmore readily moves to the nucleus and forms
a functional transcription factor in complex with HIF1b and p300. HIF, hypoxia-inducible factor; PHD, prolyl hydroxylase domain; VHL, von Hippel-Lindau E3
ubiquitin ligase; OH, prolyl hydroxylation; Ac, lysine acetylation; Ub, ubiquitination; ROS, reactive oxygen species.
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Reviewcatalytic iron and inhibition of PHD activity. In this way, the HIF
response can also be turned on downstream of increased
ROS, a common scenario in cancer [108,109].
Modulation of HIF by Sirtuins
Several studies have shown that the stress- and nutrient-sensing
pathways that coordinate HIF activity also intersect with sirtuins
at numerous nodes. For example, multiple sirtuins oppose HIF-
driven metabolic rewiring (Figure 2). Elaborate control mecha-
nisms enforced by SIRT1, SIRT2, SIRT3, SIRT6 and SIRT7
counter HIF activity to keep glucose metabolism in check [13].
In the nucleus, there is complex and considerable interplay be-
tween SIRT1 and HIF, in line with the role of SIRT1 as a promoter
of oxidative metabolism and mitochondrial function (Figure 2A).
Under normoxia, SIRT1 inhibits the basal HIF response by pro-
moting stability of the VHL transcript to drive degradation of
HIFa [50]. SIRT1 further inactivates HIF1a in the nucleus by
removing an acetyl group that is key to the interaction between
HIF1a and p300 [110]. Under hypoxia, the gradual drop in
NAD+decreasesSIRT1 function andcontributes toHIF activation
[110], which the authors of this study propose synergizes with
intratumoral PHD inhibition to maximize HIF-driven glycolysis.
Dioum et al. [111] show that, despite declining NAD+, residually
active SIRT1 can deacetylate and activate HIF2a under hypoxia,
helping drive a switch toward isoform-specific target genes (dis-
cussed further below). Interestingly, SIRT1 is a HIF1 and HIF2Current Biology 25, R569target gene [112]. It is possible that upregulation of SIRT1 expres-
sion under hypoxia serves tobuild apool of SIRT1 that can rapidly
dampen the HIF signal as soon as adequate oxygen is achieved.
A similar rationale has been suggested to explain why some PHD
family members are HIF target genes [105].
Also in the nucleus, SIRT6 represses HIF transcriptional activ-
ity to limit glycolysis in cancer (Figure 2A) [113]. First, SIRT6
deacetylates histone H3K9 on the promoter of HIF target
genes, aiding in gene silencing. SIRT6 also directly interacts
with and inhibits HIF1a on hypoxia-responsive elements of
glycolytic genes. Loss of SIRT6 in mouse embryonic fibroblasts
(MEFs) boosts expression of key glycolytic enzymes, including
pyruvate dehydrogenase kinase 1 (PDK1). Elevated PDK1 was
additionally shown to be vital for the transformation phenotype
of SIRT6-deficient MEFs [77]. The authors of this study further
show that glycolysis is increased upon SIRT6 conditional
knockout in an APCmin/+ mouse model of colon cancer and is
linked to increased tumor incidence [77].
Nuclear SIRT7 in cell culture has been shown to inhibit the HIF
response by decreasing HIF1a and HIF2a protein levels [114].
The mechanism remains to be elucidated, but appears to be
independent of SIRT7 catalytic activity as well as PHD- and pro-
teasome-mediated degradation pathways. Of note, SIRT2 de-
acetylates and represses HIF1a in the cytosol [115]. However,
this interaction has been less extensively studied.–R583, June 29, 2015 ª2015 Elsevier Ltd All rights reserved R573
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bolism and limits HIF-driven glycolysis by two mechanisms: de-
acetylation and coordination of ROS signaling (Figure 2A). SIRT3
boosts mitochondrial metabolism by deacetylating and acti-
vating enzymes involved in the TCA cycle and fatty acid oxida-
tion, including succinate dehydrogenase (SDH), long chain
acyl-CoA dehydrogenase (LCAD), glutamate dehydrogenase
(GDH) and isocitrate dehydrogenase 2 (IDH2) [15]. In tandem,
SIRT3 limits glycolytic metabolism by coordinating a multi-
pronged strategy to decrease ROS (discussed further below)
and reduce HIF function. By repressing ROS, SIRT3 promotes
PHD activity and HIF degradation. SIRT3 loss dramatically
boosts ROS, which is proposed to deactivate PHD family mem-
bers and consequently stabilize HIF1a (Figure 2B) [76,116].
Indeed, in SIRT3-deficient MEFs, increased ROS promotes a
HIF-mediated transition to the Warburg effect [76].
Thus, loss of sirtuin function has been shown in many cases
to shift the cell toward glycolytic metabolism in a process that
is amenable to transformation (Figure 2B). In cancer cell lines
and sirtuin knockout mouse models, low expression of SIRT1,
SIRT3 and SIRT6 correlates with increased levels of HIF1 target
genes, including the glucose transporter GLUT1 as well as
enzymes involved in glycolysis and lactate production, including
hexokinase (HK), PDK1, phosphoglycerate kinase 1 (PGK1) and
lactate dehydrogenase (LDHA) [50,76,113].
Additional Glycolytic Regulation by Sirtuins
Aside from HIF regulation, sirtuins can modulate glycolysis in
other ways. SIRT1 has been shown to regulate glycolytic gene
expression downstream of the transcriptional activator MYC,
although there are conflicting reports concerning the direction
of this modulation [117–120]. Loss of SIRT3 in cancer cells
additionally boosts glycolytic metabolism via pyruvate dehydro-
genase (PDH), the major enzyme that channels glucose-derived
pyruvate into the TCA cycle. SIRT3 deacetylates and activates
the PDH catalytic subunit E1a, which directs pyruvate to the
TCA cycle [121,122]. In the absence of SIRT3, pyruvate entry
into the TCA cycle is blocked. This is thought to enable glycolytic
intermediates to be redirected toward biosynthetic pathways
and lactate production. Overexpression of a constitutively de-
acetylated mimetic of PDH in MCF7 breast cancer cells resulted
in a less transformed phenotype in soft agar assays, while
a constitutively acetylated mimetic — which mimics loss of
SIRT3 — had a more highly transformed phenotype [122].
Sirtuin-mediated Regulation of Gluconeogenesis in
Cancer
Gluconeogenesis is a lesser-studied arm of glucose metabolism
in cancer. A number of sirtuins coordinate gluconeogenesis, and
the links to cancer are just beginning to be explored [15]. Phys-
iologically, glucose production occurs in the liver and to a small
extent the kidneys in order to maintain blood glucose between
meals. However, recent studies demonstrate that cancer cells
may operate at least portions of the gluconeogenic pathway.
Leithner et al. [123] found that lung cancer cell lines and tissue
samples overexpress PCK2, the mitochondrial isoform of phos-
phoenolpyruvate carboxykinase, a gluconeogenic gene. Meta-
bolic tracing demonstrated that lung cancer cells convert lactate
to pyruvate, then to oxaloacetate via pyruvate carboxylase, and
then to phosphoenolpyruvate via PCK2. This pathway generates
glycolytic intermediates in cancer cells deprived of glucose. OfR574 Current Biology 25, R569–R583, June 29, 2015 ª2015 Elseviernote, SIRT6 represses gluconeogenic gene expression in con-
cert with p53, the histone acetyltransferase GCN5, the transcrip-
tion factor FOXO1 and the transcriptional coactivator peroxi-
some proliferator-activated receptor g coactivator 1a (PGC-1a)
[124,125]. Zhang et al. [125] observed that the tumor suppressor
p53 boosts SIRT6 expression in order to limit gluconeogenesis, a
finding observed in both liver and colon cancer cell lines. The au-
thors propose that suppressing gluconeogenesis via SIRT6 may
be an additional anti-neoplastic function of p53. Future studies
are needed to explore whether regulation of gluconeogenesis
by other sirtuins is meaningful for cancer metabolism.
Alternative Fuel Sources in Cancer and Their
Coordination by Sirtuins
Beyond rewired glucose utilization, many cancers additionally or
alternatively display addiction to fatty acids or amino acids, such
as glutamine. An intensely studied use of these alternative fuels
is anaplerosis, the process of refilling the TCA cycle. Anaplerotic
pathways provide alternative entry sites to generate TCA cycle
intermediates, which are often used for anabolic and bioener-
getic purposes in cancer [126]. In many healthy tissues, PDH is
the major enzyme that channels glucose-derived pyruvate into
the TCA cycle [127]. PDH converts pyruvate to acetyl-CoA,
and then acetyl-CoA condenses with oxaloacetate to form cit-
rate. However, PDH activity is often limited in cancer; addition-
ally, roadblocks at other steps in the TCA cycle or shunting of
metabolites toward biosynthetic pathways can limit production
of oxaloacetate, which is needed to fuel subsequent rounds of
the TCA cycle [126]. In cancer, the TCA cycle can be refueled
by alternative pathways including glutaminolysis, reverse TCA
cycling and fatty acid oxidation.
Regulation of Glutamine Anaplerosis by Sirtuins
A major driver of glutamine metabolism in cancer is the MYC
family of transcriptional activators, including MYC (c-MYC),
L-MYC and N-MYC. This family is known to ubiquitously amplify
expression of most genes undergoing transcription, and MYC
target sequences have been identified in 30% of all genes
[128]. In tumors, aberrant upregulation of specific gene sets by
MYC is linked to growth advantages in cancer cells. Specifically,
MYC boosts glutaminemetabolism by increasing the expression
of glutamine transporters as well as enzymes involved in direct-
ing glutamine toward the TCA cycle, including glutaminase (GLS)
[129]. Many sirtuins have been linked to the regulation of
MYC, but SIRT6 has most strongly been shown to coordinate
glutamine metabolism via MYC [77]. By deacetylating H3K56
residues at MYC target gene promoters, SIRT6 suppresses
MYC transcription activity specifically toward genes involved in
glutamine as well as glucose metabolism. Accordingly, SIRT6-
deficient MEFs show increased glutamine uptake, an advantage
that may promote the increased growth of SIRT6-deficient MEF
xenograft models compared with wild type [77]. SIRT7 also sup-
presses MYC, while SIRT1 boosts MYC activity, and future
studies may reveal the relevance of these interactions for gluta-
mine metabolism in cancer [128].
SIRT4 coordinates glutamine anaplerosis in an alternative
manner. SIRT4 shuts down an access point that directs gluta-
mine into the TCA cycle (Figure 3A). In cancer cells, the
ability of SIRT4 to restrict the supply of this alternative fuel limits
tumorigenesis [71]. SIRT4 impedes glutamine anaplerosis byLtd All rights reserved
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Figure 3. Sirtuin-mediated regulation of TCA cycle anaplerosis.
(A) SIRT4 leads to repression of glutamine anaplerosis. SIRT4 expression is strongly induced in response to various cellular stresses, including dysfunctional
mTORC1 andDNA damage. The connections betweenmTORC1, DNA damage and SIRT4 are unclear. In cancer cells, induction of SIRT4 limits entry of glutamine
into the TCA cycle, in part by ADP-ribosylating and inhibiting GDH. (B) SIRT1 promotes glutamine anaplerosis and reductive carboxylation during chronic
acidosis. Chronic acidosis can occur in cancer cells due to a metabolic switch to increased glycolysis and lactate production. Shunting pyruvate toward lactate
can deplete the TCA cycle, driving the need for anaplerosis by other fuels. SIRT1 is activated by chronic acidosis. Under this condition, SIRT1 deacetylates HIF1a.
Deacetylation inhibits HIF1a but activates HIF2a, leading to expression of a specific subset of target genes (in red) that promote glutamine anaplerosis and
reductive carboxylation. SLC1A5 is induced to increase glutamine import into mitochondria. GLS1 is induced to convert glutamine to glutamate. IDH1 is induced
to redirect a-ketoglutarate towards isocitrate via a reductive carboxylation. GDH, glutamate dehydrogenase; GLS1, glutaminase isoform 1; IDH1, isocitrate
dehydrogenase 1.
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ReviewADP-ribosylating and inhibiting GDH [28]. To direct glutamine to-
ward the TCA cycle, glutamine can be converted to glutamate by
the glutaminase family of enzymes. Glutamate is then converted
to the TCA cycle intermediate a-ketoglutarate by mitochondrial
GDH [130] or alternatively by transaminases. In cancer cells,
DNA damage dramatically induces SIRT4 expression by an
unknown mechanism, and glutamine anaplerosis is inhibited
[71]. Consequently, TCA cycle intermediates are depleted
and, via mechanisms yet to be elucidated, the cell cycle stalls.
This SIRT4-mediated metabolic pause allows time for DNA
repair before the cell proceeds through the cell cycle. In the
absence of SIRT4, glutamine anaplerosis remains activated
even during DNA damage. As a consequence, DNA damage per-
sists and cellular proliferation and transformative properties are
increased, possibly due to newly occurring DNA mutations.
In related studies, Csibi et al. [72] found that mTOR complex 1
(mTORC1), a serine/threonine kinase that drives cellular nutrient
uptake and proliferation, inhibits SIRT4-mediated repression of
anaplerosis (Figure 3A). mTORC1 represses SIRT4 expression
by inhibiting CREB2, a transcription factor that induces SIRT4
[72]. In MEFs with hyperactivated mTORC1, SIRT4 expression
was decreased, thus activating glutamine metabolism and ana-
plerosis. High mTORC1 signaling commonly occurs in cancer
and is proposed to benefit cancer cell growth and survival by
increasing glutaminolysis via SIRT4 repression. In future studies,
it will be interesting to examine whether mTOR signaling con-
verges on DNA damage responses via SIRT4 (Figure 3).
Sirtuins and Reverse TCA Cycling
Although the TCA cycle had long been thought to operate in one
direction, it is now known that at least a portion of the TCA cycle
operates in reverse in some cancer cells, particularly in responseCurrent Biology 25, R569to redox stress, impaired respiration or hypoxia [131–133]. For-
ward TCA cycling requires pyruvate-derived acetyl-CoA to
condense with oxaloacetate and form citrate. Under harsh
conditions, such as cells undergoing proliferation in hypoxia, py-
ruvate is directed almost entirely toward lactate [134]: acetyl-
CoA may be sufficiently depleted such that forward TCA cycling
is limited. In this case, an alternative pathway is needed for cit-
rate production. Citrate is especially essential for cancer cells
because it is a key building block for fatty acid synthesis [134].
In cancer cells, glutamine-derived a-ketoglutarate can undergo
reductive carboxylation catalyzed by IDH1 or IDH2 to generate
citrate [135,136].
A recent study shows that SIRT1 promotes reductive car-
boxylation (Figure 3B) [137]. In diverse cancer cell lines, pro-
longed acidosis (pH 6.5), which mimics extensive lactate pro-
duction, upregulates genes important for reverse TCA cycle
flux in a SIRT1-dependent manner. Mechanistically, under low
pH SIRT1 deacetylates HIF1a and 2a. Deacetylation inhibits
HIF1a but activates HIF2a. By activating HIF2a, SIRT1 triggers
the expression of key target genes, including the glutamine
transporter SLC1A5, the mitochondrial glutaminase isoform 1
(GLS1) and IDH1. Thus, the SIRT1/HIF2a axis promotes a meta-
bolic shift to reductive glutaminemetabolism in order to maintain
levels of TCA cycle intermediates under the harsh conditions
experienced by cancer cells.
Sirtuins and Subcellular Metabolic Crosstalk
A fertile area for future sirtuin research is thepossible linkbetween
cancer and transcriptional control of mitochondrial biogenesis
andoxidativemetabolism.PGC-1a is amaster transcriptional co-
activator of mitochondrial metabolism and oxidative phosphory-
lation [138]. It is known that increased mitochondrial biogenesis–R583, June 29, 2015 ª2015 Elsevier Ltd All rights reserved R575
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Figure 4. Roles of sirtuins in ROS defense.
Sirtuins coordinate a multi-faceted regimen to
limit ROS. In the nucleus, SIRT1 deacetylates a
number of transcriptional regulators to boost
gene expression programs that increase antioxi-
dant defenses, limit ROS production and drive
apoptosis in the event of uncontrollable ROS. In
the cytosol, SIRT2 deacetylates FOXO to drive its
nuclear import and activity. SIRT2 also deacety-
lates and activates the glycolytic enzyme PGAM.
Activated PGAM boosts conversion of 3-phos-
phoglycerate to 2-phoshoglycerate. PGAM pro-
motes production of the antioxidant molecule
NADPH, whereas a buildup of 3-phosphoglyc-
erate would otherwise inhibit NADPH synthesis. In
mitochondria, SIRT3 boosts oxidative capacity
and limits ROS production via the deacetylation
and activation of subunits in all five electron
transport chain (ETC) complexes, including SDH-
A which dually serves as a TCA cycle enzyme that
generates FADH2. SIRT3 interacts with FOXO3a to
elevate expression of ROS defense pathways in
both the nucleus and mitochondria. SIRT3 also
drives antioxidant strategies to clear ROS. De-
acetylation and activation of IDH2 generates the
antioxidant molecule NADPH. Finally, SIRT3 de-
acetylates and activates SOD2, an enzyme that
clears superoxide. PGAM, phosphoglycerate
mutase; SDH-A, succinate dehydrogenase A; IDH2, isocitrate dehydrogenase 2; SOD2, superoxide dismutase; a-kg, a-ketoglutarate; FAD, flavin adenine
dinucleotide; HSF1, heat shock factor protein 1; NRF2, nuclear erythroid factor 2-related factor 2; PGC-1a, peroxisome proliferator-activated receptor g
coactivator 1a.
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Reviewand respiration driven by PGC-1a promote tumor cell invasion
and metastasis [139]. Further, SIRT1 and SIRT3 can promote
mitochondrial metabolism by turning on PGC-1a-mediated tran-
scriptional programs [140]; however, the direct connections be-
tween sirtuins, mitochondrial biogenesis and cancer metabolism
are unclear. Under fasting conditions, SIRT1 deacetylates and
activates PGC-1a [141]. Additionally, SIRT3 enhances expres-
sion of PGC-1a and is essential for turning on PGC-1a-induced
mitochondrial biogenesis [142,143]. Thereby, these sirtuins
promote efficient energy production during nutrient deprivation.
By favoring mitochondrial metabolism over glycolytic meta-
bolism, it is reasonable to hypothesize on the one hand that sir-
tuins hinder the metabolic changes needed for cellular transfor-
mation. However, on the other hand functional mitochondria
are still vital for an established cancer cell population to grow
and metastasize [144], and therefore sirtuin-induced upregula-
tion of mitochondrial metabolism may be one reason why sirtuin
expression can benefit many existing cancers.
Sirtuin-driven Mitochondrial Programs for ROS
Homeostasis
The role of ROS in cancer is complex. High levels of ROS have
been linked to cancer incidence in numerous studies [145–
147]. ROS production can be increased by inefficiencies or stall-
ing in the electron transport chain. ROS have both adverse and
beneficial consequences on cancer cells, which may in part be
determined by the stage of tumor progression or specific can-
cer-associated mutations [109]. First, at excessive levels ROS
can damage cellular machinery, including proteins, lipids, DNA
and RNA. By causing genetic damage, ROS may have muta-
genic and pro-tumorigenic capacities. ROS also serve as impor-
tant signaling molecules that can drive growth and cell division in
cancer [148–150]. For example, ROS have been shown to stim-
ulate the phosphoinositide 3-kinase (PI3K) signaling pathway, aR576 Current Biology 25, R569–R583, June 29, 2015 ª2015 Elseviermajor driver of cell growth that is hyperactivated inmany cancers
[109]. ROS activates PI3K by inhibiting the major negative regu-
lator of this pathway, PTEN [151]. Mechanistically, cytosolic ROS
oxidizes the catalytic cysteine residue of PTEN and promotes
formation of a disulfide bond to block PTEN function and enable
unrestrained PI3K activity [152]. ROS additionally boosts activity
of AKT, a mediator of the PI3K pathway, by blocking the activity
of a phosphatase that otherwise inhibits AKT [153].
While in some contexts ROS boosts cellular transformation
and cancer cell growth, high levels of ROS have been shown in
other contexts to act as a pro-apoptotic signal instructing cancer
cells to die [154,155]. Accelerated metabolism in cancer often
generates high ROS levels. Because ROS can reach toxic con-
centrations, adaptive mechanisms must be put in place by can-
cer cells to restore ROS homeostasis and allow survival of tumor
cells [156,157]. Therefore, many cancer cells upregulate antiox-
idant pathways that endow tumors with additional stress protec-
tion. In this way, antioxidant programs may actually promote the
progression of established tumors [158–161].
Coordination of ROS by Nuclear and Cytosolic Sirtuins
Several sirtuins have major roles in preventing excessive,
damaging levels of ROS (Figure 4). In the nucleus, SIRT1 pro-
motes ROS defense via deacetylation of key transcriptional
regulators of stress resistance, including p53, FOXO proteins,
PGC-1a, heat shock factor protein 1 (HSF1) and nuclear
erythroid factor 2-related factor 2 (NRF2) [19,162]. These targets
increase antioxidant defenses, limit ROS production and drive
apoptosis in the event of uncontrollable ROS. For example, in
response to oxidative stress or nutrient deprivation, SIRT1 de-
acetylates FOXO [163,164]. This promotes nuclear retention of
FOXO where it can turn on oxidative stress resistance genes,
such as those encoding mitochondrial superoxide dismutase 2
(SOD2), catalase and the pro-apoptotic factor Bim. SIRT2 can
also deacetylate cytosolic FOXO, causing it to move to andLtd All rights reserved
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Reviewremain in the nucleus. By upregulating Bim, SIRT2 was shown to
promote cell deathwhen cells are under severe stress [165]— an
appropriate response that can benefit survival of the surrounding
tissue. When PGC-1a is deacetylated by SIRT1, this directs
PGC-1a toward a specific gene set that promotes increased
mitochondrial biogenesis and oxidative capacity to limit ROS
production [166].
In the cytosol, SIRT2 also combats ROS by promoting the
generation of the antioxidant molecule NADPH (Figure 4). In
response to H2O2 treatment in cell culture, SIRT2 deacetylates
and activates phosphoglycerate mutase (PGAM) [167]. PGAM
is a glycolytic enzyme that converts 3-phopshoglycerate to
2-phosphoglycerate. In the absence of SIRT2, PGAM is less
active and levels of 3-phosphoglycerate increase. Not only is
glycolysis impeded, but also high amounts of 3-phosphoglyc-
erate inhibit 6-phosphogluconate dehydrogenase (6PGD), an
enzyme in the pentose phosphate pathway that produces
NADPH. Thus, SIRT2 is required to activate PGAM and help
maintain NADPH synthesis for use in clearing ROS.
Regulation of ROS by Mitochondrial Sirtuins
Mitochondrial SIRT3 is a major player in cellular antioxidant
strategies. SIRT3 coordinates a multi-faceted post-translational
program to reduceROS (Figure 4). First, SIRT3 limitsROSproduc-
tion by promoting efficient electron flow through the ETC. SIRT3
deacetylates and activates specific subunits in all five ETC com-
plexes. SIRT3 activates complex I [168] and SDH-A in complex II
[169,170], components of the ETC where electrons are initially
donated. SDH-A dually functions as a TCA cycle enzyme that
oxidizes succinate to fumarate while converting flavin adenine
dinucleotide (FAD) to FADH2. Electrons from FADH2 are directly
fed into the SDH-B subunit of complex II and then on through
the ETC. By activating complex I and II, SIRT3 enables NADH
and FADH2 to more readily contribute electrons to the ETC.
SIRT3 activates complex III [171,172] and IV [43,51] to further
promote efficient electron flow and generation of a proton
gradient. Activation of complex V (ATP synthase) boosts ATP
production [172,173]. By activating all ETC components, SIRT3
increases mitochondrial oxidative capacity, prevents ETC stalling
and limits ROS production. Of note, mitochondrial SIRT5 sup-
presses SDH activity, possibly via desuccinylation, but the rele-
vance to cancer is not known [174]. In cancer cells grown in galac-
tose — a condition that increases the dependency on oxidative
phosphorylation — SIRT3 has been shown to boost the ETC in
an additional way, via deacetylation of cyclophilin D, leading to
release of HK2 from mitochondria [175]. HK2 in mitochondria is
linked to increased relianceonglycolyticmetabolism,but released
HK2 stimulates oxidative phosphorylation.
In addition to limiting ROS production, SIRT3 also promotes
ROS clearance. SIRT3 deacetylates SOD2, a key mitochondrial
enzyme in antioxidant defense which initiates ROS detoxification
by converting superoxide to H2O2 [176,177]. Mice heterozygous
for SOD2 have more DNA damage and 100% increased cancer
incidence than wild-type controls [178]. To complete ROS clear-
ance, H2O2 is reduced to water by the antioxidant glutathione.
SIRT3 indirectly boosts levels of glutathione. By deacetylating
and activating the TCA cycle enzyme IDH2, SIRT3 promotes
conversion of isocitrate to a-ketoglutarate in a reaction that
simultaneously produces NADPH [179]. NADPH is a reducing
agent with antioxidant functions that generates reduced gluta-Current Biology 25, R569thione. Finally, SIRT3 has been shown to boost transcription of
antioxidant enzymes by interacting with mitochondrial FOXO3a
and boosting its affinity for promoters of antioxidant genes in
the nucleus and promoters of genes encoding oxidative phos-
phorylation subunits in mitochondria [171,180,181]. Through
these multiple mechanisms, SIRT3 boosts cellular oxidative ca-
pacity, decreases ETC stalling and promotes antioxidant de-
fenses.
Recent studies suggest SIRT3 is not the only mitochondrial
sirtuin that coordinates ROS; SIRT5 also limits ROS by at least
two mechanisms. SIRT5 desuccinylates and activates SOD1,
the largely cytosolic isoform of SOD that is also present at low
amounts in mitochondria [182]. SIRT5 additionally boosts tran-
scription of NRF2, consequently promoting gene expression
programs important for maintaining redox homeostasis [183].
Through regulation ofROS,mitochondrial sirtuins play acritical
yet complex role in cancer progression [184]. By decreasing
ROS, SIRT3 has the capacity to limit tumorigenesis. In healthy
cells, SIRT3 decreases ROS, maintains PHD activity and re-
presses HIF, as described above [76,116]. Consequently SIRT3
represses the transition to the Warburg effect, thus restricting a
metabolic pathway that is quite often vital to neoplastic transfor-
mation [185]. SIRT3 may further impede cancer onset by limiting
DNA damage caused by ROS [171]. Additionally, in pancreatic
cancer cell lines, SIRT3 suppression of ROS was shown to limit
proliferation via coordination of ironmetabolism [186]. By limiting
ROS, SIRT3 represses redox-sensitive iron-responsive proteins,
thus downregulating an iron-related gene set that includes the
transferrin receptor. In the absence of SIRT3, increased levels
of transferrin receptor correlated with a growth advantage for
pancreatic cancer cells, at least in part due to an abundance of
intracellular iron, an essential cofactor in DNA synthesis.
While limiting ROS levels helps sirtuins act as tumor suppres-
sors in certain cases, established tumors may benefit from
maintaining sirtuin function to avoid ROS-induced apoptosis.
For example, high SIRT3 expression was observed in oral squa-
mous cell carcinoma cell lines and human samples [81], and in
cardiomyocytes, overexpression of SIRT3 conferred resistance
to genotoxic and oxidative stress-inducing agents, including
camptothecin and H2O2 [187]. Thus, it is tempting to speculate
that, in an already established tumor, high sirtuin expression
may promote cancer cell viability by limiting ROS, a pro-
apoptotic signal that would otherwise instruct cancer cells to
die. Future studies are needed to reveal the range of cancer con-
texts in which ROS are either beneficial or harmful and in which
sirtuins have tumor-suppressive or tumor-promoting functions.
Conclusions
The role of sirtuins in cancer echoes that of other stress sensors
such as AMPK [188], whereby distinct cancer contexts ultimately
determine whether these enzymes confer pro- or anti-cancer
properties. On the one hand, sirtuin activation promotes good
health by restricting metabolic pathways linked to neoplastic
transformation, and sirtuin loss predisposes animal models to
cancer. On the other hand, sustained sirtuin activity in the stress-
ful environment of a tumor may endow cancer cell survival
mechanisms or resistance to chemotherapeutics. Overall, our
knowledge of the seven sirtuins in distinct cancer contexts
is revealing metabolic susceptibilities that can potentially be–R583, June 29, 2015 ª2015 Elsevier Ltd All rights reserved R577
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Reviewtargeted in cancer treatment. Along these lines, several diverse
classes of sirtuin inhibitors, including tenovins, are currently be-
ing tested for anti-cancer properties in animal models and in the
clinic [19,189,190]. Many more connections between sirtuins
and cancer metabolism likely remain to be discovered based
on the numerous substrates, both known and unknown, that
have not yet been tested for a role in cancer. Additionally,
we are rapidly learning the importance of new and diverse
metabolic pathways involved in cancer. A number of sirtuins
coordinate lipogenesis and fatty acid oxidation, both pathways
recently highlighted for involvement in tumor metabolism. The
role of sirtuins in these processes in cancer is not yet known.
Sirtuin research has revealed interconnected metabolic and
signaling pathways that drive tumor biology and could be
specifically targeted in cancer treatment. Additionally, sirtuin
expression could be considered for its utility as a metabolic
biomarker to potentially designate the most promising therapeu-
tic approach in a new era of metabolically-based precision
medicine.
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